We are serious about changing the face of medicine. As we pioneer new science and expand a diverse research pipeline, we launched The Lens: a thought-leadership platform to share our team’s expertise in precision medicine for oncology and rare diseases.
Browse our archive of blog posts and webinars below.

American Society of Hematology (ASH) Annual Meeting
December 8, 2019
PIONEER: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of Avapritinib in Patients with Indolent or Smoldering Systemic Mastocytosis with Symptoms Inadequately Controlled with Standard Therapy
Read moreConnective Tissue Oncology Society (CTOS) Annual Meeting
November 14, 2019
Clinical Response to Avapritinib by RECIST and Choi Criteria in ≥ 4th Line and PDGFRA Exon 18 Gastrointestinal Stromal Tumors (GIST)
Read moreConnective Tissue Oncology Society (CTOS) Annual Meeting
November 14, 2019
Avapritinib for the Treatment of GIST: Analysis of Efficacy, Safety, and Patient Management Strategies at the Recommended Phase 2 Dose
Read moreISPOR Europe
November 7, 2019
Psychometric Evaluation of the Advanced Systemic Mastocytosis Symptom Assessment Form (AdvSM-SAF) in patients with Advanced Systemic Mastocytosis
Read moreISPOR Europe
November 7, 2019
Psychometric Performance of the Indolent Systemic Mastocytosis Symptom Assessment Form (ISM-SAF)
Read moreCancer Discovery
October 1, 2019
First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma
Read moreCancer Discovery
October 1, 2019
Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma
Read moreEuropean Society for Medical Oncology (ESMO) Annual Meeting
September 30, 2019
Treatment With Pralsetinib (BLU-667), a Potent and Selective RET Inhibitor, Provides Rapid Clearance of ctDNA in Patients With RET-Altered Non-Small Cell Lung Cancer (NSCLC) and…
Read moreASBMR 2019 Annual Meeting
September 22, 2019
A clinical update on BLU-782, an investigational selective ALK2 inhibitor in development for fibrodysplasia ossificans progressiva (FOP)
Read moreIASLC World Conference on Lung Cancer
September 9, 2019
Pralsetinib (BLU-667) demonstrates robust activity in RET-fusion-driven intracranial tumor models
Read moreEuropean Hematology Association (EHA) Annual Meeting
June 15, 2019
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Induces Complete and Durable Responses in Patients (pts) with Advanced Systemic Mastocytosis (AdvSM)
Read moreASCO 2019: Advancing Cancer Treatment with Precision Therapies
May 31, 2019
At the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting, a key focus will be precision therapy – targeting genetic drivers of cancer with…
Read moreBlueprint Medicines Recognizes International FOP Awareness Day
April 23, 2019
Letter from Marion Dorsch, Chief Scientific Officer Today, Blueprint Medicines stands with the patient community and recognizes International Fibrodysplasia Ossificans Progressiva (FOP) Awareness Day. In…
Read moreHow Our Research Platform Helped Accelerate the Discovery of BLU-667
April 10, 2019 by Jason Brubaker
Discovering potent and selective kinase drugs is a challenging endeavor. Setting up and completing a screen of a new drug target against a compound library…
Read moreAmerican Association for Cancer Research (AACR) Annual Meeting
March 30, 2019
Discovery of BLU-667 for RET-driven cancers
Read moreBlueprint Medicines Introduces The Lens
January 2, 2019 by Marion Dorsch, Chief Scientific Officer
Welcome to The Lens, our new thought leadership platform to share our team’s expertise in precision medicine. We are pioneers in this rapidly evolving field,…
Read moreAmerican Society of Hematology (ASH) Annual Meeting
December 2, 2018
Avapritinib, a Potent and Selective Inhibitor of KIT D816V, Improves Symptoms of Advanced Systemic Mastocytosis (AdvSM) (oral presentation)
Read moreConnective Tissue Oncology Society (CTOS) Annual Meeting
November 15, 2018
Avapritinib is Highly Active and Well-tolerated in Patients With Advanced GIST Driven by a Diverse Variety of Oncogenic Mutations in KIT and PDGFRA (oral presentation)
Read moreEuropean Society for Medical Oncology (ESMO) Annual Meeting
October 22, 2018
Correlation of ctDNA and Response in Patients with PDGFRα D842 GIST Treated with Avapritinib (poster presentation)
Read moreEuropean Society for Medical Oncology (ESMO) Annual Meeting
October 22, 2018
An Open-label, Randomized, Phase 3 Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Metastatic or Unresectable Gastrointestinal Stromal Tumor (poster presentation)
Read moreAmerican Thyroid Association (ATA) Annual Meeting
October 6, 2018
Clinical activity of BLU-667, a highly selective RET inhibitor, in advanced RET-altered thyroid cancers: updated results from the phase 1 ARROW study (oral presentation)
Read moreClinical Cancer Research
October 1, 2018
Robust activity of avapritinib, potent and highly selective inhibitor of mutated KIT, in patient-derived xenograft models of gastrointestinal stromal tumors
Read moreAmerican Society for Bone and Mineral Research (ASBMR) Annual Meeting
September 30, 2018
BLU-782: A highly selective ALK2 inhibitor, designed specifically to target the cause of fibrodysplasia ossificans progressiva
Read moreIASLC World Conference on Lung Cancer
September 26, 2018
Activity of osimertinib and the selective RET inhibitor BLU-667 in an EGFR-mutant patient with acquired RET rearrangement (oral presentation)
Read moreCancer Discovery
September 26, 2018
Landscape of acquired resistance to osimertinib in EGFR-mutant NSCLC and clinical validation of combined EGFR and RET inhibition with osimertinib and BLU-667 for acquired RET…
Read moreEuropean Hematology Association (EHA) Annual Meeting
June 15, 2018
Avapritinib (BLU-285), a Selective KIT Inhibitor, is Associated with High Response Rate and Tolerable Safety Profile in Advanced Systemic Mastocytosis: Results of a Phase 1…
Read moreAmerican Association for Cancer Research (AACR) Annual Meeting
April 15, 2018
Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in ARROW, a phase 1 study of advanced, RET-altered solid tumors (oral presentation)
Read moreCancer Discovery
April 15, 2018
Precision targeted therapy with BLU-667 for RET-driven cancers
Read moreAmerican Society of Hematology (ASH) Annual Meeting
December 10, 2017
Clinical activity in a Phase 1 study of BLU-285, a potent, highly-selective inhibitor of KIT D816V in advanced systemic mastocytosis (plenary oral presentation)
Read moreConnective Tissue Oncology Society (CTOS) Annual Meeting
November 10, 2017
Clinical activity of BLU-285, a highly potent and selective KIT/PDGFRα inhibitor designed to treat gastrointestinal stromal tumor (GIST) (oral presentation)
Read moreScience Translational Medicine
November 1, 2017
A precision therapy against cancers driven by KIT/PDGFRA mutations
Read moreMolecular Targets and Cancer Therapeutics (AACR – NCI – EORTC)
October 29, 2017
BLU-667 is a Potent and Highly Selective RET Inhibitor Being Developed for RET-Driven Cancers
Read moreInternational Liver Cancer Association (ILCA) Annual Conference
September 17, 2017
(Clinical activity Of BLU-554, a potent, highly-selective FGFR4 inhibitor in advanced HCC with FGFR4 pathway activation (oral presentation)
Read moreEuropean Society for Medical Oncology (ESMO) Annual Meeting
September 10, 2017
Phase 1 Safety and Clinical Activity of BLU-554 in advanced hepatocellular carcinoma (oral presentation)
Read moreWorld Congress on Thyroid Cancer
July 30, 2017
BLU-667 is a potent and highly selective RET inhibitor in development for RET-driven thyroid cancers
Read moreAmerican Society of Clinical Oncology (ASCO) Annual Meeting
June 5, 2017
Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) (oral presentation)
Read moreAmerican Association for Cancer Research (AACR) Annual Meeting
April 2, 2017
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
Read moreAmerican Association for Cancer Research (AACR) Annual Meeting
April 2, 2017
BLU-285: A potent and highly selective inhibitor designed to target malignancies driven by KIT and PDGFRα mutations (oral presentation)
Read moreAmerican Society of Hematology (ASH) Annual Meeting
December 4, 2016
Preliminary Safety and Activity in a Phase 1 study of BLU-285, a Potent, Highly-Selective Inhibitor of KIT D816V in Advanced Systemic Mastocytosis (SM) (oral presentation)
Read moreEORTC – NCI – AACR Molecular Targets and Cancer Therapeutics Symposium
December 1, 2016
Preliminary safety and activity in a first-in-human Phase 1 study of BLU-285, a potent, highly selective inhibitor of KIT and PDGFRα activation loop mutants in…
Read moreMolecular Targets and Cancer Therapeutics (EORTC – NCI – AACR)
November 29, 2016
First-in-human study of BLU-554, a potent, highly selective FGFR4 inhibitor designed for hepatocellular carcinoma (HCC) with FGFR4 pathway activation (poster presentation)
Read moreAmerican Association for Cancer Research (AACR) Annual Meeting
April 18, 2016
The development of Potent and Selective RET inhibitors
Read moreCancer Discovery
March 16, 2015
First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway
Read moreNature Communications
September 19, 2014
Genomic analyses of gynaecologic carcinosarcomas reveal frequent mutations in chromatin remodelling genes
Read more